AbbVie’s Profit Forecast Cut Sends Shockwaves Through Market
Published on 10/13/2025 at 17:09 | Redaktion boerse-global.de
A substantial $2.7 billion charge has delivered a significant blow to biotechnology leader AbbVie, forcing the company to dramatically lower its 2025 earnings guidance just ahead of quarterly results. This unexpected development has left investors questioning what prompted the sudden profit warning and whether the company’s long-term growth narrative remains intact.
The profit forecast revision stems from unanticipated research and development expenses totaling $2.7 billion. These IPR&D (In-Process Research and Development) charges typically emerge from acquisition activities or licensing agreements and have impacted AbbVie’s third-quarter results. Consequently, the company has slashed its adjusted earnings per share projection from the previously anticipated range of $11.88-$12.08 down to just $10.38-$10.58. For the current quarter, management forecasts merely $1.74-$1.78 per... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
